SpaceX~$1TSpaceX~$1T
Insider Buying
Subscribe
All stock lists
ATTO

Attovia Therapeutics, Inc. (NASDAQ:ATTO)

US · Delayed Price · Currency is USD
Healthcare · Biotechnology
$15.10-$0.48 (-3.08%)
 
Market cap
$690M
Insider Score
Health Score
Analyst consensus
Listed since
Aug 5, 2026
Market Cap$690.26M-31.1%
Revenue (ttm)$1.44M
Net Income-$78.87M
EPS-$1.80
Shares Out45.71M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume372,219
Open$15.40
Previous Close$15.58
Day's Range$14.80 - $15.46
52-Week Range$12.94 - $28.00
Betan/a
AnalystsBuy
Price Target$45.33(+200.20%)
Earnings DateFeb 8, 2027

About ATTO

A clinical-stage biopharmaceutical company developing biotherapeutics for immune-mediated diseases using its ATTOBODY biologics platform. The company's lead candidate, ATTO-1310, targets interleukin-31 (IL-31), known as the 'itch cytokine,' for the treatment of chronic pruritic diseases including atopic dermatitis. Its pipeline also includes multi-specific candidates for other inflammatory diseases.

Address
1091 Industrial Rd, Ste 310, San Carlos, CA, 94070, US
Market Cap
690 million
Employees
50
Industrial Classification
Biotechnology

What Are Insiders Doing?

Open-market buy / sell balanceNet Buying
Sold
$33.75K
Bought
$65.80M

View the trades behind this meter — each links to its SEC Form 4 →

Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.

When insiders bought and sold

1 year · open-market trades only
Closing Price Purchase Sale
$12.63$19.73$26.83SepNov

Analyst consensus

Moderate Buy
2 Buy0 Hold0 Sell

2 firms rating ATTO in the last 3 months, one vote each. Issuer-paid research is not counted.

Financial Health Score
Fair
From ATTO’s reported statements · Q3 2026 (trailing 12 months)

Next catalysts

1 Day
-3.08%
5 Days
+0.60%
1 Month
+4.14%
6 Months
-31.05%
1 Year
-31.05%

$ATTO stock is featured in our Insider Trades datasets.

→ All Stock Lists

Recently reported changes in ATTO holdings by institutional investors

Scanning latest 13F filings…

Latest 0 13F filings · Source: SEC EDGAR

View all institutional owners →

Insider Trading

Quarterly net insider trading by ATTO's directors and management

Net Shares Purchased by Insiders−4M−2M02025Q42026Q12026Q22026Q32026Q4

Source: SEC EDGAR (Form 4)

Corporate Lobbying

ATTO Estimated quarterly lobbying spending

Source: U.S. Senate LDA

ATTO Revenue by Segment

$19.68MTotal
Clinical, manufacturing, and preclinical services$15.06M76.52%
Personnel-related costs$3.48M17.70%
Professional consulting services$717.00K3.64%
Facilities and overhead costs$420.00K2.13%

As of: Q3 2026 (Sep 30, 2026) · Source: SEC EDGAR (10-Q)

U.S. Patents

New ATTO patent grants

Loading patent grants…

Source: USPTO Open Data Portal

Government Contracts

Estimated quarterly amount awarded to ATTO from public contracts

Source: USAspending.gov

Top ETF Holders

ETFs with the largest estimated holdings in ATTO

VTIVanguard Morningstar Total Stock Market ETF$6.80M
VXFVanguard Extended Market ETF$2.98M
SCHASchwab U.S. Small-Cap ETF$1.36M
VTWOVanguard Russell 2000 ETF$270.41K
SCHBSchwab U.S. Broad Market ETF$169.56K
VTWGVanguard Russell 2000 Growth ETF$27.07K

Estimated from each fund’s disclosed top holdings × AUM

Bull Case vs Bear Case

AI-generated from ATTO’s recent data — informational, not investment advice

Generating analysis…

What’s Behind the Score

Insider Activity
60% of score
61.86
Analyst Ratings
40% of score
99
News & Sentiment
No data yet
—

Recent Insider Activity

Buys
9
Sells
2
Buy Value
$65.80M
Distinct Buyers
6

Frequently Asked Questions

Disclaimer — Informational only — not investment advice. Insider transaction data is sourced from SEC Form 4 filings; market data from public feeds and may be delayed. The Insider Score is a proprietary score for research purposes and does not predict future performance. Always do your own research.